{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibq7ytrtykh7eo2y35ntoeih5lfvilitpjdlchok64kk32gabwkpi",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mnd7ui5kkih2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreif2t436mwi2lbeqwqcfee4jczg45s6k6x4lhligxekrtes5fqrlzy"
    },
    "mimeType": "image/jpeg",
    "size": 310562
  },
  "path": "/news/2026-06-theranostic-approach-effectively-neuroendocrine-prostate.html",
  "publishedAt": "2026-06-02T13:50:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A novel theranostic approach that targets RET—a newly identified biomarker for neuroendocrine prostate cancer—enables high-contrast PET imaging and effective, safe treatment for this highly aggressive malignancy. Because this disease is often poorly visualized with prostate-specific membrane antigen (PSMA)-based imaging, the RET approach offers an important alternative when conventional molecular imaging and PSMA-directed therapies are unsuitable. This research is being presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.",
  "title": "New theranostic approach effectively detects and treats neuroendocrine prostate cancer"
}